Emergent BioSolutions | EBS - Dochód Netto





Dochód Netto Zmiana Data
Acadia Pharmaceuticals USD 31.5M 27.86M 2026-06
Akebia Therapeutics USD -12.24M 12.78M 2025-12
ALKERMES USD 501K 66.98M 2026-06
Alnylam Pharmaceuticals USD 164.49M 41.5M 2026-06
Amarin USD -1.22M 6.51M 2025-12
ANI Pharmaceuticals USD 24.71M 4.78M 2026-06
BioMarin Pharmaceutical USD 44.76M 60.76M 2026-06
Coherus Biosciences USD -37.64M 2.11M 2025-12
Emergent BioSolutions USD -261.3M 78.3M 2023-06
Exelixis USD 212.05M 1.58M 2026-06
Glaxosmithkline GBP 1.74B 890.94M 2026-03
Heron Therapeutics USD -2.95M 14.54M 2025-12
Ionis Pharmaceuticals USD -114.65M 21.65M 2026-06
Ironwood Pharmaceuticals USD 3.19M 457K 2024-12
Lexicon Pharmaceuticals USD -15.53M 2.76M 2025-12
Lonza CHF 426M 119M 2025-06
Merck USD -1.34B 2.9B 2026-06
Moderna USD -1.34B 517M 2026-03
Myriad Genetics USD -7.9M 19.5M 2025-12
Nektar Therapeutics USD -44.9M 8.82M 2026-03
Neurocrine Biosciences USD 144.4M 53.5M 2026-06
Pacira USD 4.65M 1.74M 2026-06
Pfizer USD -248M 2.94B 2026-06
PTC Therapeutics USD -2.81M 132.16M 2026-03
Sanofi EUR 343M 1.27B 2026-06
Sarepta Therapeutics USD 330.96M 743.18M 2026-03
United Therapeutics USD 333M 58.1M 2026-06
Vanda Pharmaceuticals USD -18.9M 13.58M 2024-12